Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Elanco Animal Health Inc has a consensus price target of $15.55 based on the ratings of 11 analysts. The high is $20 issued by Morgan Stanley on November 15, 2022. The low is $9 issued by Goldman Sachs on April 25, 2023. The 3 most-recent analyst ratings were released by Stifel on May 19, 2025, May 8, 2025, and April 14, 2025, respectively. With an average price target of $14.67 between Stifel, there's an implied 9.29% upside for Elanco Animal Health Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
05/19/2025 | Buy Now | 19.23% | Stifel | Jonathan Block72% | $15 → $16 | Maintains | Buy | Get Alert |
05/08/2025 | Buy Now | 11.77% | Stifel | Jonathan Block72% | $13 → $15 | Maintains | Buy | Get Alert |
04/14/2025 | Buy Now | -3.13% | Stifel | Jonathan Block72% | $15 → $13 | Maintains | Buy | Get Alert |
03/06/2025 | Buy Now | -10.58% | Piper Sandler | David Westenberg59% | $16 → $12 | Maintains | Neutral | Get Alert |
02/26/2025 | Buy Now | 26.68% | UBS | Andrea Alfonso62% | $18 → $17 | Maintains | Buy | Get Alert |
02/26/2025 | Buy Now | -3.13% | Morgan Stanley | Erin Wright75% | $14 → $13 | Maintains | Equal-Weight | Get Alert |
02/26/2025 | Buy Now | 11.77% | Stifel | Jonathan Block72% | $16 → $15 | Maintains | Buy | Get Alert |
02/26/2025 | Buy Now | 41.58% | Barclays | Balaji Prasad55% | $20 → $19 | Maintains | Overweight | Get Alert |
02/21/2025 | Buy Now | 19.23% | Stifel | Jonathan Block72% | $18 → $16 | Maintains | Buy | Get Alert |
01/29/2025 | Buy Now | 4.32% | Morgan Stanley | Erin Wright75% | $15 → $14 | Maintains | Equal-Weight | Get Alert |
01/07/2025 | Buy Now | 34.13% | Stifel | Jonathan Block72% | $20 → $18 | Maintains | Buy | Get Alert |
12/09/2024 | Buy Now | 34.13% | UBS | Andrea Alfonso62% | → $18 | Initiates | → Buy | Get Alert |
12/02/2024 | Buy Now | 4.32% | Leerink Partners | Daniel Clark41% | → $14 | Initiates | → Market Perform | Get Alert |
11/08/2024 | Buy Now | 49.03% | Barclays | Balaji Prasad55% | $19 → $20 | Maintains | Overweight | Get Alert |
10/28/2024 | Buy Now | 41.58% | Barclays | Balaji Prasad55% | $22 → $19 | Maintains | Overweight | Get Alert |
09/23/2024 | Buy Now | 63.93% | Barclays | Balaji Prasad55% | $21 → $22 | Maintains | Overweight | Get Alert |
09/19/2024 | Buy Now | 49.03% | Stifel | Jonathan Block72% | $20 → $20 | Reiterates | Buy → Buy | Get Alert |
09/19/2024 | Buy Now | 11.77% | Morgan Stanley | Erin Wright75% | $17 → $15 | Downgrade | Overweight → Equal-Weight | Get Alert |
07/01/2024 | Buy Now | 19.23% | Piper Sandler | David Westenberg59% | $19 → $16 | Maintains | Neutral | Get Alert |
06/28/2024 | Buy Now | 56.48% | Barclays | Balaji Prasad55% | $23 → $21 | Maintains | Overweight | Get Alert |
05/13/2024 | Buy Now | 41.58% | Piper Sandler | David Westenberg59% | $18 → $19 | Reiterates | Neutral → Neutral | Get Alert |
05/09/2024 | Buy Now | 71.39% | Barclays | Balaji Prasad55% | $19 → $23 | Maintains | Overweight | Get Alert |
03/12/2024 | Buy Now | 34.13% | Piper Sandler | David Westenberg59% | $12 → $18 | Reiterates | Neutral → Neutral | Get Alert |
02/27/2024 | Buy Now | 4.32% | Goldman Sachs | Nathan Rich42% | $12.5 → $14 | Maintains | Sell | Get Alert |
02/27/2024 | Buy Now | 26.68% | Morgan Stanley | Erin Wright75% | $16 → $17 | Maintains | Overweight | Get Alert |
02/27/2024 | Buy Now | 41.58% | Barclays | Balaji Prasad55% | $18 → $19 | Maintains | Overweight | Get Alert |
01/17/2024 | Buy Now | -6.86% | Goldman Sachs | Nathan Rich42% | $10 → $12.5 | Maintains | Sell | Get Alert |
01/05/2024 | Buy Now | 49.03% | Stifel | Jonathan Block72% | $13 → $20 | Upgrade | Hold → Buy | Get Alert |
12/19/2023 | Buy Now | 26.68% | Jefferies | Glen Santangelo49% | → $17 | Initiates | → Buy | Get Alert |
12/15/2023 | Buy Now | 19.23% | Morgan Stanley | Erin Wright75% | → $16 | Upgrade | Equal-Weight → Overweight | Get Alert |
12/07/2023 | Buy Now | -3.13% | Stifel | Jonathan Block72% | $12 → $13 | Maintains | Hold | Get Alert |
11/13/2023 | Buy Now | -10.58% | Piper Sandler | David Westenberg59% | $11 → $12 | Maintains | Neutral | Get Alert |
11/08/2023 | Buy Now | 19.23% | Morgan Stanley | Erin Wright75% | $17 → $16 | Maintains | Equal-Weight | Get Alert |
10/30/2023 | Buy Now | -10.58% | Stifel | Jonathan Block72% | $13 → $12 | Maintains | Hold | Get Alert |
08/14/2023 | Buy Now | -3.13% | Piper Sandler | David Westenberg59% | $9 → $13 | Maintains | Neutral | Get Alert |
08/09/2023 | Buy Now | -29.21% | Goldman Sachs | Nathan Rich42% | $8.5 → $9.5 | Maintains | Sell | Get Alert |
08/08/2023 | Buy Now | -29.21% | Goldman Sachs | Nathan Rich42% | $8.5 → $9.5 | Maintains | Sell | Get Alert |
04/26/2023 | Buy Now | -32.94% | Goldman Sachs | Nathan Rich42% | $10.5 → $9 | Maintains | Sell | Get Alert |
04/25/2023 | Buy Now | -32.94% | Goldman Sachs | Nathan Rice57% | $10.5 → $9 | Maintains | Sell | Get Alert |
04/20/2023 | Buy Now | 4.32% | Barclays | Balaji Prasad55% | → $14 | Upgrade | Equal-Weight → Overweight | Get Alert |
02/22/2023 | Buy Now | 4.32% | Barclays | Balaji Prasad55% | $18 → $14 | Maintains | Equal-Weight | Get Alert |
01/30/2023 | Buy Now | 41.58% | Morgan Stanley | Erin Wright75% | $20 → $19 | Maintains | Equal-Weight | Get Alert |
11/15/2022 | Buy Now | 49.03% | Morgan Stanley | Joseph Moore71% | $21 → $20 | Maintains | Equal-Weight | Get Alert |
11/14/2022 | Buy Now | 11.77% | Piper Sandler | David Westenberg59% | $21 → $15 | Maintains | Neutral | Get Alert |
11/09/2022 | Buy Now | -10.58% | Goldman Sachs | Nathan Rich42% | $19 → $12 | Maintains | Sell | Get Alert |
10/17/2022 | Buy Now | 49.03% | JP Morgan | Chris Schott59% | $24 → $20 | Maintains | Neutral | Get Alert |
10/07/2022 | Buy Now | 56.48% | Morgan Stanley | Joseph Moore71% | $22 → $21 | Maintains | Equal-Weight | Get Alert |
09/12/2022 | Buy Now | 34.13% | Barclays | Balaji Prasad55% | $32 → $18 | Maintains | Equal-Weight | Get Alert |
08/18/2022 | Buy Now | 63.93% | Morgan Stanley | Erin Wright75% | $37 → $22 | Downgrade | Overweight → Equal-Weight | Get Alert |
08/17/2022 | Buy Now | 56.48% | Piper Sandler | David Westenberg59% | $22 → $21 | Maintains | Neutral | Get Alert |
08/16/2022 | Buy Now | — | JP Morgan | Chris Schott59% | — | Downgrade | Overweight → Neutral | Get Alert |
07/21/2022 | Buy Now | 41.58% | Goldman Sachs | Nathan Rich42% | $32 → $19 | Downgrade | Buy → Sell | Get Alert |
07/18/2022 | Buy Now | 138.45% | JP Morgan | Chris Schott59% | $37 → $32 | Maintains | Overweight | Get Alert |
07/12/2022 | Buy Now | 63.93% | Piper Sandler | David Westenberg59% | → $22 | Initiates | → Neutral | Get Alert |
06/24/2022 | Buy Now | 63.93% | Stifel | Jonathan Block72% | $30 → $22 | Maintains | Hold | Get Alert |
The latest price target for Elanco Animal Health (NYSE:ELAN) was reported by Stifel on May 19, 2025. The analyst firm set a price target for $16.00 expecting ELAN to rise to within 12 months (a possible 19.23% upside). 20 analyst firms have reported ratings in the last year.
The latest analyst rating for Elanco Animal Health (NYSE:ELAN) was provided by Stifel, and Elanco Animal Health maintained their buy rating.
The last upgrade for Elanco Animal Health Inc happened on January 5, 2024 when Stifel raised their price target to $20. Stifel previously had a hold for Elanco Animal Health Inc.
The last downgrade for Elanco Animal Health Inc happened on September 19, 2024 when Morgan Stanley changed their price target from $17 to $15 for Elanco Animal Health Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Elanco Animal Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Elanco Animal Health was filed on May 19, 2025 so you should expect the next rating to be made available sometime around May 19, 2026.
While ratings are subjective and will change, the latest Elanco Animal Health (ELAN) rating was a maintained with a price target of $15.00 to $16.00. The current price Elanco Animal Health (ELAN) is trading at is $13.42, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.